Vimarsana.com

Latest Breaking News On - Christophera viehbacher - Page 4 : vimarsana.com

Alzheimer's Drug Aduhelm Pulled Off the Market

Alzheimer's drug Aduhelm to be pulled off market as the drugmaker focuses on Leqembi, another Alzheimer's medication. Learn more about Alzheimer's treatments.

United-states
Americans
Christophera-viehbacher
Alzheimer-association
Drug-administration
Drugmaker-biogen
Alzheimer-39-s
Lzheimer-39s-drugs
Lzheimer-39s-drug-aduhelm
Leqembi
Ementia

Biogen Discontinues Alzheimer Disease Treatment Aduhelm

The decision to discontinue Aduhelm was not related to any safety or efficacy concerns.

Christophera-viehbacher
Drug-administration

Biogen Inc.: Biogen to Realign Resources for Alzheimer's Disease Franchise

Biogen Inc.: Biogen to Realign Resources for Alzheimer's Disease Franchise
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United-states
Cambridge
Cambridgeshire
United-kingdom
Chuck-triano
Priya-singhal
Jack-cox
Christophera-viehbacher
Stefan-klotter
Facebook
Nasdaq
Head-of-development-at-biogen

Biogen (BIIB) to Realign Resources for Alzheimer's Disease Franchise

Biogen (BIIB) to Realign Resources for Alzheimer's Disease Franchise
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United-states
Priya-singhal
Christophera-viehbacher
Head-of-development-at-biogen
Nasdaq
Biogen-inc
Chief-executive-officer
Drug-administration

Biogen to Realign Resources for Alzheimer's Disease Franchise

Company to reprioritize resources allocated to ADUHELM® (aducanumab-avwa) to advance LEQEMBI® (lecanemab-irmb) and to develop new treatment modali...

Cambridge
Cambridgeshire
United-kingdom
United-states
Christophera-viehbacher
Chuck-triano
Priya-singhal
Jack-cox
Head-of-development-at-biogen
Youtube
Nasdaq
Exchange-commission

Biogen to cease production of controversial Alzheimer's drug

The drugmaker will discontinue development and marketing for Aduhelm, a landmark Alzheimer's disease treatment.

Christophera-viehbacher
Drugmaker-biogen
Biogen
Lzheimer-39s-disease
Da
Accelerated-approval
Esearch-and-development
Hristophera-viehbacher

Biogen to cease production of controversial Alzheimer's drug

Biogen to cease production of controversial Alzheimer's drug
politico.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from politico.com Daily Mail and Mail on Sunday newspapers.

Christophera-viehbacher

Biogen to cease production of controversial Alzheimer's drug

The drugmaker will discontinue development and marketing for Aduhelm, a landmark Alzheimer's disease treatment.

Christophera-viehbacher

Top 3 Healthcare Stock Picks for the New Year

InvestorPlace - Stock Market News, Stock Advice & Trading Tips After lagging most sectors in 2023, healthcare stocks could deliver substantial...

Japan
Japanese
Mongkolchon-akesin-shutterstock
Novo-nordisk
Christophera-viehbacher
Pfizer
Goldman-sachs
Eli-lilly
Mongkolchon-akesin

Biogen : to Participate in the 42nd Annual J.P. Morgan Healthcare Conference -December 19, 2023 at 04:11 pm EST

Cambridge, MA, Biogen, Inc. announced today that Christopher A. Viehbacher, President and Chief Executive Officer, will participate in a fireside chat during the 42nd Annual J.P....

Cambridge
Cambridgeshire
United-kingdom
Karen-jewell
Christophera-viehbacher
Facebook
Nasdaq
Linkedin
Biogen-inc
Youtube
Chief-executive-officer
Markets

vimarsana © 2020. All Rights Reserved.